Macrogenics Inc (MGNX)
14.38
-1.32
(-8.44%)
USD |
NASDAQ |
Apr 25, 16:00
14.38
0.00 (0.00%)
After-Hours: 20:00
Macrogenics Cash from Financing (TTM): 150.36M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 150.36M |
September 30, 2023 | 151.45M |
June 30, 2023 | 101.54M |
March 31, 2023 | 101.74M |
December 31, 2022 | 1.659M |
September 30, 2022 | 1.10M |
June 30, 2022 | 20.07M |
March 31, 2022 | 22.16M |
December 31, 2021 | 122.78M |
September 30, 2021 | 123.08M |
June 30, 2021 | 178.17M |
March 31, 2021 | 274.84M |
December 31, 2020 | 174.34M |
September 30, 2020 | 173.54M |
June 30, 2020 | 99.51M |
March 31, 2020 | 1.129M |
December 31, 2019 | 119.97M |
September 30, 2019 | 120.15M |
June 30, 2019 | 120.24M |
March 31, 2019 | 223.37M |
December 31, 2018 | 104.99M |
Date | Value |
---|---|
September 30, 2018 | 104.88M |
June 30, 2018 | 105.89M |
March 31, 2018 | 35.87M |
December 31, 2017 | 35.35M |
September 30, 2017 | 35.48M |
June 30, 2017 | 35.34M |
March 31, 2017 | 1.738M |
December 31, 2016 | 1.854M |
September 30, 2016 | 1.612M |
June 30, 2016 | 141.58M |
March 31, 2016 | 141.63M |
December 31, 2015 | 204.35M |
September 30, 2015 | 204.32M |
June 30, 2015 | 63.52M |
March 31, 2015 | 63.59M |
December 31, 2014 | 77.44M |
September 30, 2014 | 162.24M |
June 30, 2014 | 162.20M |
March 31, 2014 | 162.62M |
December 31, 2013 | 85.87M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
1.10M
Minimum
Sep 2022
274.84M
Maximum
Mar 2021
108.31M
Average
120.15M
Median
Sep 2019
Cash from Financing (TTM) Benchmarks
Allurion Technologies Inc | 95.99M |
United Therapeutics Corp | -11.90M |
MEI Pharma Inc | -11.66M |
Marinus Pharmaceuticals Inc | 26.63M |
Voyager Therapeutics Inc | 33.64M |